Opinion|Videos|December 22, 2023
Patient Characteristics in Real-World Study on Teclistamab
Author(s)Danai Dima, MD
Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.
Advertisement
Episodes in this series
Advertisement
Related to this article
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5